<DOC>
	<DOC>NCT02373046</DOC>
	<brief_summary>This is a randomized, single-center, open-label, 2-sequence, 2-period, single-dose, crossover study to assess the bioequivalence and the total 24-hour urinary glucose excretion (UGE) of 400 mg LX4211 administered as a single 400-mg tablet compared to 2 × 200-mg tablets in healthy subjects under fasted conditions.</brief_summary>
	<brief_title>Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets</brief_title>
	<detailed_description />
	<criteria>Adult subjects ≥18 to ≤55 years of age Willing and able to provide written informed consent Presence of clinically significant physical, laboratory, or ECG findings that, in the opinion of the Investigator and/or Sponsor, may interfere with any aspect of study conduct or interpretation of results Existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism, or excretion of LX4211 History of renal disease, or significantly abnormal kidney function test at Screening History of hepatic disease, or significantly abnormal liver function tests at Screening History of any clinically relevant psychiatric, renal, hepatic, pancreatic, endocrine, cardiovascular, neurological, hematological, or GI abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>